Fig 1: Illustration of the preparation and the anti-metastatic HCC strategy of GalNAc-modified AHPMA and DMAEMA-based polymeric micelles carried with gene/chemotherapy through the VEGF/VEGFR signaling pathway.
Fig 2: (A) Western blot analysis of the expression of VEGF and VEGFR2 after treatment with different formulations for 48h (left panel). Quantified results of Western blot analysis (right panel). (B) Transwell migration assay of C5WN1 cells with different formulations for 12 h. Photograph (magnification, ×100) (Left panel) and cell counts after treatment with different formulations (right panel). Group: (1) Blank group, (2) siVEGF, (3) siVEGF@GalNAc-pDMA, (4) siVEGFR2, (5) siVEGFR2@GalNAc-pDMA, (6) siRNA (siVEGF+siVEGFR2), (7) siRNA@GalNAc-pDMA, (8) 5-FU/siRNA@GalNAc-pDMA. Each group was treated with the same dose of the following components: 5-FU at 50 µg mL-1, GalNAc-pDMA at 300 µg mL-1 and siRNA at 3.5 µg mL-1. Data are expressed as the mean ± SD. Compared with the control: * p < 0.05 and *** p < 0.001.
Supplier Page from Abcam for Mouse VEGFR2 Antibody Pair - BSA and Azide free